|
Real-time
Euronext Paris
03:38:54 2026-08-17 EDT
|
5-day change | 1st Jan Change | ||
| 68.92 EUR | -2.16% |
|
-1.60% | +10.45% |
| 07-23 | Eurofins Scientific SE, H1 2026 Earnings Call, Jul 23, 2026 | |
| 07-23 | Eurofins Scientific: BioPharma's slowdown raises questions on 2026 organic growth target |  |
Company Valuation: Eurofins Scientific SE
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 20,893 | 12,900 | 11,336 | 9,273 | 11,036 | 12,228 | - | - |
| Change | - | -38.26% | -12.13% | -18.2% | 19.02% | 10.8% | - | - |
| Enterprise Value (EV) 1 | 23,132 | 15,739 | 14,041 | 12,269 | 14,677 | 15,577 | 15,242 | 14,997 |
| Change | - | -31.96% | -10.79% | -12.62% | 19.63% | 6.13% | -2.15% | -1.61% |
| P/E | 27.8x | 22.2x | 45.4x | 26.9x | 28x | 23.5x | 18.6x | 15.6x |
| PBR | 4.49x | 2.7x | 2.24x | 1.73x | 2.56x | 2.63x | 2.39x | 2.2x |
| PEG | - | -1x | -0.8x | 0.7x | 1.3x | 0.7x | 0.7x | 0.8x |
| Capitalization / Revenue | 3.11x | 1.92x | 1.74x | 1.33x | 1.51x | 1.61x | 1.53x | 1.43x |
| EV / Revenue | 3.44x | 2.34x | 2.16x | 1.77x | 2.01x | 2.05x | 1.9x | 1.75x |
| EV / EBITDA | 12.2x | 10.4x | 10.3x | 7.91x | 8.94x | 8.89x | 8.02x | 7.24x |
| EV / EBIT | 15.7x | 15.2x | 16.7x | 12.1x | 13.6x | 13.8x | 12.2x | 10.8x |
| EV / FCF | 22.8x | 23.2x | 29.6x | 15.3x | 16.7x | 17.9x | 16x | 14.4x |
| FCF Yield | 4.39% | 4.3% | 3.38% | 6.53% | 5.97% | 5.59% | 6.23% | 6.94% |
| Dividend per Share 2 | 1 | 1 | 0.5 | 0.5 | 0.72 | 0.808 | 0.9164 | 0.9723 |
| Rate of return | 0.92% | 1.49% | 0.85% | 1.01% | 1.15% | 1.15% | 1.3% | 1.38% |
| EPS 2 | 3.91 | 3.02 | 1.3 | 1.83 | 2.23 | 2.999 | 3.796 | 4.504 |
| Distribution rate | 25.6% | 33.1% | 38.5% | 27.3% | 32.3% | 26.9% | 24.1% | 21.6% |
| Net sales 1 | 6,718 | 6,712 | 6,515 | 6,951 | 7,296 | 7,588 | 8,009 | 8,548 |
| EBITDA 1 | 1,902 | 1,513 | 1,364 | 1,552 | 1,641 | 1,753 | 1,900 | 2,071 |
| EBIT 1 | 1,473 | 1,037 | 842 | 1,017 | 1,079 | 1,132 | 1,254 | 1,392 |
| Net income 1 | 783 | 606 | 310 | 406 | 475 | 530.9 | 659.7 | 817.4 |
| Net Debt 1 | 2,239 | 2,839 | 2,705 | 2,996 | 3,641 | 3,349 | 3,014 | 2,768 |
| Reference price 2 | 108.80 | 67.06 | 58.98 | 49.31 | 62.40 | 70.44 | 70.44 | 70.44 |
| Nbr of stocks (in thousands) | 192,035 | 192,365 | 192,194 | 188,049 | 176,864 | 173,599 | - | - |
| Announcement Date | 2/22/22 | 3/1/23 | 2/27/24 | 1/30/25 | 1/29/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 23.48x | 2.05x | 8.89x | 1.15% | 14.16B | |
| 33.04x | 5.91x | 17.56x | 0.97% | 48.42B | |
| -21.14x | 288.75x | -21.43x | -.--% | 43.66B | |
| 45.52x | 5.25x | 28.69x | -.--% | 39.51B | |
| 30.48x | 3.03x | 13.08x | -.--% | 38.95B | |
| 30.58x | 8.82x | 22.17x | 0.38% | 32.61B | |
| 32.9x | 5.38x | 24.45x | -.--% | 16.15B | |
| 74.93x | 3.96x | 15.35x | -.--% | 13.37B | |
| 27.64x | 1.83x | 11.26x | -.--% | 12.59B | |
| Average | 30.83x | 36.11x | 13.33x | 0.28% | 28.82B | |
| Weighted average by Cap. | 26.49x | 52.81x | 12.13x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ERF Stock
- Valuation Eurofins Scientific SE
Select your edition
All financial news and data tailored to specific country editions
